Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| International Society for Gastrointestinal Hereditary Tumours |
RCV000781997 | SCV000920454 | pathogenic | Lynch syndrome | 2018-10-18 | reviewed by expert panel | curation | Multifactorial likelihood analysis posterior probability > 0.99 (0.998) |
| Ambry Genetics | RCV001014369 | SCV001175067 | likely pathogenic | Hereditary cancer-predisposing syndrome | 2021-09-16 | criteria provided, single submitter | clinical testing | The p.V695M variant (also known as c.2083G>A), located in coding exon 13 of the MSH2 gene, results from a G to A substitution at nucleotide position 2083. The valine at codon 695 is replaced by methionine, an amino acid with highly similar properties. This alteration has been classified as pathogenic using the following lines of evidence: in silico prediction models, segregation with disease, and clinical phenotype which includes tumor characteristics (Thompson BA et al. Hum. Mutat. 2013 Jan;34:200-9; Thompson BA et al. Nat. Genet. 2014 Feb;46:107-15; available at [www.insight-group.org/variants/classifications/]). In a massively parallel cell-based functional assay testing susceptibility to a DNA damaging agent, 6-thioguanine (6-TG), this variant was determined to be functionally deleterious (Jia X et al. Am J Hum Genet, 2021 01;108:163-175). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the majority of available evidence to date, this variant is likely to be pathogenic. |